Health Economics›Glioblastoma›Recurrent disease non-curative therapy randomized data

Recurrent disease non-curative therapy randomized data

Glioblastoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lomustine and Bevacizumab Variant #01 Partial	—	R 57 246	42d	—	~9.1 mo	~2	~R 114 493 PFS proxy · indirect	1
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	—	~9.0 mo	~52	~R 992 271 PFS proxy · indirect	2
Hydroxyurea and Imatinib Variant #01	—	R 5 867	28d	~1.4 mo	—	~2	~R 11 735 PFS proxy · indirect	1
PCV Variant #02 Partial	—	R 327	56d	—	~57.6 mo	~6	~R 1 959 PFS proxy · indirect	3
Hydroxyurea monotherapy Variant #01	—	R 265	28d	~1.4 mo	—	~2	~R 529 PFS proxy · indirect	1
Carmustine monotherapy Variant #01 Partial	—	—	42d	—	—	~1	—	—
TTFields monotherapy Variant #01	—	—	—	—	~6.6 mo	—	—	1
Lomustine monotherapy Variant #01 Partial	—	—	42d	~1.6 mo	~8.6 mo	~2	—	4
Gliadel wafer monotherapy Variant #01	—	—	—	—	~8.8 mo	—	—	1

9 of 9 regimens shown